HAEMONETICS CORP (HAE)
↓ Download CSV- Sector Manufacturing
- Incorporated MA
- Fiscal year ends Mar 28
In fiscal 2026, HAEMONETICS CORP reported revenue of $1.33B, down 2.0% from the prior year. The company was profitable, with a net margin of 7.3% and a gross margin of 59.0%.
Key ratios (FY2026)
59.0%
Gross margin
11.7%
Operating margin
7.3%
Net margin
12.2%
Return on equity
-2.0%
Revenue growth (YoY)
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.20M | $870.46M | $988.48M | $967.58M | $903.92M | $886.12M |
| Cost of Revenue | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M | $472.62M | $503.97M | $550.04M | $492.01M | $507.62M |
| Gross Profit | $787.59M | $748.96M | $691.55M | $615.10M | $505.50M | $397.84M | $484.51M | $417.54M | $411.91M | $378.49M |
| Operating Income | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M | $89.75M | $103.35M | $83.55M | $56.16M | -$19.38M |
| Net Income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M | $79.47M | $76.53M | $55.02M | $45.57M | -$26.27M |
| EPS (Diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | $-0.51 |
| Total Assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B | $1.27B | $1.27B | $1.24B | $1.24B |
| Shareholders' Equity | $796.32M | $820.84M | $959.96M | $818.00M | $749.42M | $731.67M | $587.11M | $667.87M | $752.43M | $739.61M |
| Cash & Equivalents | $245.44M | $306.76M | $178.80M | $284.47M | $259.50M | $192.31M | $137.31M | $169.35M | $180.17M | $139.56M |
| Operating Cash Flow | $293.22M | $181.72M | $181.75M | $273.06M | $172.26M | $108.81M | $158.22M | $159.28M | $220.35M | $159.74M |
| Capital Expenditures | $32.78M | $39.28M | $38.12M | $191.33M | $96.51M | $37.04M | $48.76M | $118.96M | $74.80M | $76.14M |
| Shares Outstanding | 47.35M | 50.73M | 51.40M | 51.42M | 51.35M | 51.29M | 51.81M | 52.94M | 53.50M | 51.52M |